Company news
Biosenic (EURONEXT:BIOS) news
Biosenic news releases on 6ix. Latest, Dec 14, 2025: BioSenic : Report from Auditor on ESEF format 2024 Annual Report
Press releases & updates
BioSenic : Report from Auditor on ESEF format 2024 Annual Report
December 14, 2025
BioSenic : appoints CarKath SRL, represented by Mr Eric Halioua, as chairman of the board of directors
September 25, 2025
BioSenic : provides an update on the preparation of the annual accounts and annual report for the financial year ending on 31 December 2024
August 29, 2025
BioSenic : announces the homologation by the Enterprise Court of BioSenic's amicable agreements with five main creditors to restructure over €22 million of debt and appointment of two new independent directors
August 4, 2025
BioSenic : announces partnership with 4Moving Biotech and secures its financing.
July 1, 2025
BioSenic : announces efforts to explore new strategic assets and partnerships in order to pursue its development following its recent debt restructuring
April 27, 2025
BioSenic : announces dealy in the publication of 2024 annual results and annual report.
April 27, 2025
BioSenic : Transparency notification received from ABO Infinium Americas OpCo LTD
April 6, 2025
BioSenic : reaches an agreement with two bond creditors to restructure over EUR 9 million in debt
February 18, 2025
BioSenic : Medsenic, a subsidiary of BioSenic, has signed a conditional letter of intent that could secure funding to cover part of the costs for its clinical trial on chronic graft versus host disease
December 14, 2024
BioSenic provides third quarter 2024 Business Update
October 28, 2024
BioSenic : Carole Nicco steps down from her roles as Chief Scientific and Operations Officer of BioSenic to focus on the subsidiary Medsenic SAS
October 14, 2024
BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD.
October 7, 2024
BioSenic : Transparency notification received from ABO Infinium Americas OpCo LTD.
October 7, 2024
BioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the composition of its board of directors
September 30, 2024
BioSenic : Half-year Financial Report H1 2024
September 30, 2024